Trial Profile

Phase 1 study of CERC-301 in patients with neurogenic Orthostatic Hypotension (nOH) associated with Parkinson's disease.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rislenemdaz (Primary)
Indications Orthostatic hypotension; Parkinson's disease
Focus Adverse reactions; Pharmacodynamics; Proof of concept
Sponsors Avalo Therapeutics; Cerecor

Most Recent Events

01 Jul 2019 Final Results presented in a Cerecor Inc Media Release.
01 Jul 2019 Status changed from active, no longer recruiting to completed according to a Cerecor Inc Media Release.
01 Jul 2019 According to a Cerecor Inc media release, the study enrolled 19 patients with nOH associated with Parkinson's disease of which 14 were randomized. Enrollment was closed following the positive interim results seen in April 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com